Selective Appoints Wole Coaxum as Independent Director

BMO Capital downgraded Selective Insurance Group (SIGI) to Market Perform from Outperform, keeping a $97 price target. The stock trades at about $92.78. BMO raised EPS estimates 1% on higher interest rates but said underwriting margin improvement is slower, shifting the expected timeline to about two years.

Selective Insurance Group (NASDAQ:SIGI) reported Q2 2026 revenue of $1.39 billion, up 4.5% year over year, beating Wall Street’s estimate. Non-GAAP EPS was $1.95, 16.9% above consensus. The company said it returned 45% of after-tax net income via dividends and $32 million in buybacks; operating ROE was 13.7%. Shares fell 7.5% to $90.62.

SELECTIVE INSURANCE GROUP INC (SIGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 q22026pressreleasesuppleme.htm EX-99.2 Document Exhibit 99.2 FINANCIAL SUPPLEMENT SECOND QUARTER 2026 Forward-Looking Statements Certain statements in this report, including information incorporated by reference, are “forward-looking statements” defined in the Private S

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.